⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Nerandomilast (nerandomilast) | Accelerate Your Fibrosis Research

Home/Drugs/Nerandomilast

Nerandomilast

nerandomilast

Approved

Sponsor: Kyorin Pharmaceutical

Indication: IPF

Mechanism of Action

Phosphodiesterase 4 (PDE4) inhibitor, reduces inflammation and fibrosis

Target: PDE4

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

RECRUITINGNCT06195072

Platform Clinical Study for Conquering Scleroderma

Phase:PHASE2Org:Scleroderma Research Foundation, Inc.

COMPLETED

Relevant Publications (PubMed)

Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators-a review of current insights and future direction.

Bazsó A, Szodoray P, Shoenfeld Y et al.

Autoimmun Rev2026 Mar 14

Nerandomilast.

Unknown Journal2006

Industry Payments and Prescribing Patterns of Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis in the United States.

Murayama A, Tarras ES, Freeman LM et al.

Respir Med2026 Mar 11

Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Validated Models

This drug has been validated in the following preclinical models:

NCT07100964

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT05661344

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

Phase:PHASE1Org:Boehringer Ingelheim

RECRUITINGNCT06968845

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Phase:PHASE2Org:Rein Therapeutics

RECRUITINGNCT06241560

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Phase:PHASE2Org:Boehringer Ingelheim

View all trials on ClinicalTrials.gov

Shahzad H, Afzaal U, Saleem F et al.

Clin Respir J2026 Mar

Network meta-analysis of pharmacological treatments for idiopathic pulmonary fibrosis: evaluating effects on lung function.

Yin Y, Wu X, Liu Z et al.

Front Pharmacol2026

View more on PubMed